FTC Seeks More Info On $16.5 Billion Novo/Catalent Deal
By Colin Kellaher
A $16.5 billion deal aimed at boosting Novo Nordisk's production of the weight-loss drug Wegovy is drawing extra scrutiny from U.S. antitrust regulators.
Novo Holdings, which owns a controlling stake in Novo Nordisk, in February agreed to buy contract drug maker Catalent with plans to flip three of Catalent's most critical plants to Novo Nordisk for $11 billion to help meet demand for Wegovy and its cousin diabetes drug Ozempic.
In a filing with the Securities and Exchange Commission on Friday, Catalent said the Federal Trade Commission has asked the company and Novo for additional information and documentary materials as the antitrust enforcer reviews the deal.
The so-called second request by the FTC signals the agency is reviewing whether the deal could be anticompetitive under U.S. law.
The FTC has become more active under the Biden administration in taking action against large mergers, and the agency last month sued to block Tapestry's $8.5 billion acquisition of rival Capri Holdings, saying the deal would give the combined firm too much power in the market for accessible luxury handbags.
Catalent said the company and Novo will cooperate with the FTC in an effort to obtain an antitrust green light "as expeditiously as possible," adding that they expect to complete the transaction toward the end of 2024.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 03, 2024 09:51 ET (13:51 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing